tweetindex
DE

Daphne Koller ✓

@DaphneKoller · San Francisco Bay Area · joined 29 Sep 2012

Founder and CEO of @insitro, Machine Learning pioneer, co-founder of Coursera, adjunct CS Professor at Stanford, avid traveler

37 778Followers
6Following
62Posts total
198.2KViews on collected posts

Neueste Beiträge

@DaphneKoller But I think there will be magic wand 🪄 for drug discovery and life-saving medicines, perhaps in years or decades. Small startups like us, big companies like Anthropic or OAI are creating it. So I believe we will find our magic wand for AI x Bio. 424 views · 3 likes · 0 reposts · 0 replies Open on X →
@DaphneKoller So AI is only capable of reducing the cost of clinical trials by 11-17%? And primarily in the IND-enabling portion IMHO it's mission-critical for @FDA to streamline to prevent the U.S. from falling behind in biotech https://t.co/D94Igpyh6b 1.1K views · 5 likes · 1 reposts · 0 replies Open on X →
@DaphneKoller Spot on from @DaphneKoller. Pure in silico reasoning on thinly sampled biology just generates failures at scale. The entire AI-bio thesis hinges on shifting the bottleneck from pure compute to the closed-loop physical verification layer: generating multimodal, caus 98 views · 2 likes · 0 reposts · 0 replies Open on X →
Only about a quarter of human diseases have an approved therapy. By some estimates it's a few percent. Most of those treatments slow a disease rather than stop it. Closing that gap is what the AI-cures-everything story promises. Build a system smart enough and the cures hidden h 77.7K views · 388 likes · 82 reposts · 18 replies Open on X →
I am so excited to welcome Amy to our Board of Directors! Her unique experience in combining technology and data science with drug development and regulatory policy will be invaluable to us as we move to the next phase of our journey at insitro. 14.6K views · 50 likes · 5 reposts · 11 replies Open on X →
We're thrilled to welcome Dr. Amy Abernethy to our BOD! A clinical research pioneer & hematologist-oncologist, her dedication to data-driven healthcare innovation and transformative drug development on behalf of patients align perfectly with our mission. https://t.co/FsETGqxmLB h 20.4K views · 25 likes · 4 reposts · 3 replies Open on X →
@DaphneKoller @insitro Do you see it. In front of countless media. Wear a suit. The mouth of the talk is like a river. to the end. His hype turned out to be all wrong. It's all a lie. Moreover. That's what I'm going to show you through. That's him. 13 views · 0 likes · 0 reposts · 0 replies Open on X →
@DaphneKoller @insitro Those wretched words are a mirror. The wretched nature of such people is exposed in the face of women and children. 25 views · 0 likes · 0 reposts · 0 replies Open on X →
@DaphneKoller @insitro He has completely no bottom line, shamelessly disgust.He is insulting the girl's genitals. 21 views · 0 likes · 0 reposts · 0 replies Open on X →
Come join our exec team at @insitro - https://t.co/hzFQ5gXWUp: lead our ML efforts and make a difference to patients! We are building an ML-enabled platform to advance medicines for patients in neuroscience, metabolism and oncology diseases. (Read more: https://t.co/R5jicTAU0h). 27.4K views · 88 likes · 20 reposts · 21 replies Open on X →
Excited to welcome Mike to the @insitro team! Mike has an incredible track record of innovation in clinical trial design, to deliver on the goal of accelerating impact to patients. His contributions will be transformative as we enter the next phase of our journey. 11.2K views · 25 likes · 2 reposts · 4 replies Open on X →
We’re thrilled to welcome Dr. S. Michael Rothenberg as insitro’s CMO. With 2 decades of clinical care & drug development experience, his innovations in data-driven trial design will be critical as we advance our pipeline toward the clinic. https://t.co/jfWC2RUiHC https://t.co/L4R 12.3K views · 11 likes · 3 reposts · 0 replies Open on X →
Thank you @matthewherper for the insightful coverage of our team's scientific progress, highlighting how #AI and #Biology can advance us towards our mission of bringing better medicines to patients. For more details, watch our presentation tomorrow at #jpm2024! 9.8K views · 29 likes · 1 reposts · 3 replies Open on X →
We’re excited to share @matthewherper’s new story in @statnews, which spotlights 3 new research papers posted online describing exciting developments emerging from our #ML platform across our core therapeutic areas. Read more below. #JPM24 23K views · 24 likes · 10 reposts · 0 replies Open on X →

Im Vergleich zu Konten gleicher Größe

4 Beiträge aus den letzten 90 Tagen, verglichen mit der Größenklasse 10K–100K Follower. liegt bei Reichweite und Interaktion unter vergleichbaren Konten.

Medianaufrufe784dieses Konto924Median für 10K–100K
Reichweite, %2.08%dieses Konto3.62%Median für 10K–100K
Interaktion, %0.68%dieses Konto1.52%Median für 10K–100K
KennzahlDieses KontoMedian für 10K–100KVerhältnis
Medianaufrufe pro Beitrag7849240.85×
Reichweite (Aufrufe ÷ Follower)2.08%3.62%0.57×
Interaktionsrate0.68%1.52%0.45×

Weitere Konten dieser Größe →   Mit einem anderen Konto vergleichen →   Wie diese Vergleichswerte entstehen →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

23K7 Jan
9.8K8 Jan
12.3K
11.2K
27.4K12 Jan
2118 Jan
25
1328 Jan
20.4K3 Apr
14.6K
77.7K4 Aug
98
1.1K
4245 Aug

Last 14 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.16%7 Jan
0.34%8 Jan
0.12%
0.28%
0.49%12 Jan
0.00%18 Jan
0.00%
0.00%28 Jan
0.17%3 Apr
0.45%
0.66%4 Aug
2.04%
0.52%
0.71%5 Aug

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes53.9%650 in total
Reposts10.6%128 in total
Replies5.0%60 in total
Quotes3.0%36 in total
Bookmarks27.5%331 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Ähnliche Konten